The effects of risperidone and olanzapine on the indications for clozapine

Psychopharmacology Bulletin

Volumn 34, Issue 1, 1998, Pages 83-87

  Ganguli, Rohan ^a   Brar, Jaspreet S ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Atypical antipsychotic agents; Clozapine; Indications; Olanzapine; Risperidone; Schizophrenia

Indexed keywords

CLOZAPINE; OLANZAPINE; RISPERIDONE;

ARTICLE; DRUG USE; HUMAN; MAJOR CLINICAL STUDY; PATIENT REFERRAL; PRESCRIPTION; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT INDICATION;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; HUMANS; PIRENZEPINE; RISPERIDONE; SCHIZOPHRENIA;

EID: 0031924875     PISSN: 00485764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. Am. J. Psychiatry 154 (4, Suppl.):1-63, 1997.
2. Baldessarini, RJ, and Frankenburg, FR. Clozapine. A novel antipsychotic agent. N. Engl. J. Med. 324(11):746-754, 1991.
3. Chouinard, G; Jones, B; Remington, G; Bloom, D; Addington, D; MacEwan, GW; Labelle, A; Beauclair, L; and Arnott, W. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J. Clin. Psychopharmacol. 13(1):25-40, 1993.
4. Conley, RR; Tamminga, CA; Beasley, C; and the Maryland Study Group. Olanzapine vs. chlorpromazine in treatment-resistant schizophrenia. Biol. Psychiatry 41[7, Suppl.]:73S, 1997.
5. Frances, A; Docherty, JP; and Kahn, DA. Treatment of schizophrenia. The expert consensus guideline series. J. Clin. Psychiatry 57[12B, Suppl.]:1-29, 1996.
6. Honigfeld, G, and Patin, J. A two-year clinical and economic follow-up of patients on clozapine. Hosp. Comm. Psychiatry 41(8):882-885, 1990.
7. Kane, J; Honigfeld, G; Singer, J; Meltzer, H; and the Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 45:789-796, 1988.
8. Kapur, S, and Remington, G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am. J. Psychiatry 153(4):466-476, 1996.
9. Marder, SR, and Meibach, RC. Risperidone in the treatment of schizophrenia. Am. J. Psychiatry 151(6):825-835, 1994.
10. Meltzer, HY; Burnett, S; Bastani, B; and Ramirez, LF. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp. Comm. Psychiatry 41(8):892-897, 1990.
11. Pilowsky, LS; Busatto, GF; Taylor, M; Costa, DC; Sharma, T; Sigmundsson, T; Ell, PJ; Nohria, V; and Kerwin, RW. Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine: A 1231 IBZM single photon emission tomography (SPET) study. Psychopharmacology 124(1-2):148-153, 1996.
12. Safferman, A; Lieberman, JA; Kane, JM; Szymanski, S; and Kinon, B. Update on the clinical efficacy and side effects of clozapine. Schizophr. Bull. 17(2):247-261, 1991.
13. Schotte, A; Janssen, PF; Gommeren, W; Luyten, WH; Van Gompel, P; Lesage, AS; De Loore, K; and Leysen, JE. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding. Psychopharmacology 124(1-2):57-73, 1996.
14. Smith, RC; Chua, JW; Lipetsker, B; and Bhattacharyya, A. Efficacy of risperidone in reducing positive and negative symptoms in medication-refractory schizpophrenia: An open prospective study. J. Clin. Psychiatry 57(10):460-466, 1996.
15. Tollefson, GD, and Sanger, TM. Negative symptoms: A path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am. J. Psychiatry 154(4):466-474, 1997.